ZA200605393B - Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability - Google Patents

Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Info

Publication number
ZA200605393B
ZA200605393B ZA200605393A ZA200605393A ZA200605393B ZA 200605393 B ZA200605393 B ZA 200605393B ZA 200605393 A ZA200605393 A ZA 200605393A ZA 200605393 A ZA200605393 A ZA 200605393A ZA 200605393 B ZA200605393 B ZA 200605393B
Authority
ZA
South Africa
Prior art keywords
formulations
immunogenic composition
hydrophobic proteins
improved tolerability
tolerability
Prior art date
Application number
ZA200605393A
Other languages
English (en)
Inventor
Susan Kay Hoiseth
Iii Thomas Newell Metcalf
Yury Vladimirovich Matsuka
Michael Hagen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200605393B publication Critical patent/ZA200605393B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA200605393A 2003-12-30 2006-06-29 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability ZA200605393B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53312203P 2003-12-30 2003-12-30

Publications (1)

Publication Number Publication Date
ZA200605393B true ZA200605393B (en) 2009-12-30

Family

ID=34748856

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605393A ZA200605393B (en) 2003-12-30 2006-06-29 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Country Status (13)

Country Link
US (1) US7608278B2 (ja)
EP (1) EP1699482A2 (ja)
JP (1) JP2007517057A (ja)
KR (1) KR20060108739A (ja)
CN (1) CN1901935A (ja)
AU (1) AU2004312067A1 (ja)
BR (1) BRPI0417938A (ja)
CA (1) CA2551896A1 (ja)
IL (1) IL176339A0 (ja)
MX (1) MXPA06007635A (ja)
TW (1) TW200526244A (ja)
WO (1) WO2005065708A2 (ja)
ZA (1) ZA200605393B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
JP5731109B2 (ja) * 2009-07-09 2015-06-10 東亞合成株式会社 疎水性ペプチドに対する抗体の製造方法
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
HUE052850T2 (hu) 2010-08-23 2021-05-28 Wyeth Llc Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
CN103068368A (zh) 2010-08-30 2013-04-24 霍夫曼-拉罗奇有限公司 产生四连蛋白-载脂蛋白a-i脂质颗粒的方法，脂质颗粒本身及其应用
EP2611417A2 (en) 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Method for producing a tetranectin-apolipoprotein a-1 particle, the lipid particle obtained therewith and its use
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012093732A1 (ja) * 2011-01-07 2012-07-12 セイコーエプソン株式会社 アミロイド前駆体タンパク質のシグナルペプチドに対する抗体
RU2014108240A (ru) 2011-08-25 2015-09-27 Ф. Хоффманн-Ля Рош Аг Укороченный тетранектин-аполипопротеин а-i гибридный белок, содержащая его липидная частица и их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
KR102099487B1 (ko) * 2012-05-16 2020-04-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 세포 및/또는 조직을 가용화시키기 위한 조성물
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
EP2879691B1 (en) * 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809796A1 (de) * 1988-03-23 1989-10-05 Wolfgang Prof Dr Med Bredt Verfahren zum reinigen eines 168 kd-proteins von mycoplasma pneumoniae
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
EP1150712B1 (en) 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations

Also Published As

Publication number Publication date
EP1699482A2 (en) 2006-09-13
CN1901935A (zh) 2007-01-24
IL176339A0 (en) 2006-10-05
US20070122433A1 (en) 2007-05-31
US7608278B2 (en) 2009-10-27
WO2005065708A3 (en) 2005-10-20
KR20060108739A (ko) 2006-10-18
AU2004312067A1 (en) 2005-07-21
MXPA06007635A (es) 2007-01-30
CA2551896A1 (en) 2005-07-21
WO2005065708A2 (en) 2005-07-21
TW200526244A (en) 2005-08-16
BRPI0417938A (pt) 2007-04-17
JP2007517057A (ja) 2007-06-28

Similar Documents

Publication Publication Date Title
IL176339A0 (en) Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
PL1682091T3 (pl) Kompozycje lipidów i kationowych peptydów
IL182495A0 (en) Orthogonal translation components for the in vivo incorporation of unnatural amino acids
PL377614A1 (pl) Kompozycje zawierające kwasy tłuszczowe i aminokwasy
HK1203558A1 (en) In vivo incorporation of unnatural amino acids
IL218357A0 (en) Compositions and methods of using angiopoietin-like 4 protein
IL175844A0 (en) Improved stability of progestogen formulations
EP1631308A4 (en) NOVEL METHODS AND NOVEL COMPOSITIONS FOR MUCOSAL ENHANCED DELIVERY OF PEPTIDES AND PROTEINS
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
IL174420A0 (en) Stabilized formulations of phosphatidylserine
HK1119951A1 (en) Methods and compositions for oral administration of proteins
HK1081404A1 (en) Acidic compositions comprising protein and fiber and processes of their preparation
GB0323965D0 (en) Immunogenic compositions
IL174542A0 (en) Immunogenic compositions
AU2003230761A1 (en) Polymeric micelle formulations of hydrophobic compounds and methods
PL1663928T3 (pl) Wytwarzanie kompozycji alkoksylanowej
ZA200603542B (en) Oral formulations of desoxypeganine and uses thereof
EP1684798A4 (en) RECOMBINANT INTRA-CELLULAR PATHOGENIC IMMUNOGENIC COMPOSITIONS AND APPLICATION PROCEDURES
GB2412338B (en) Surface preparation of an implant
EP1670893A4 (en) IMMUNOGENEOUS HIV COMPOSITIONS AND METHODS CONNECTED THEREWITH
IL172758A0 (en) Pharmaceutical compositions containing balaglitazone and methods for the preparation thereof
HUP0400737A3 (en) Use of l-carnitine for preparation of compositions for stabilizing the proteins
EP1534756A4 (en) EXPRESSION OF HYDROPHOBIC PROTEINS
AP2004003081A0 (en) Immunogenic formulations of variable peptidic epitopes and for preparation thereof
EP1333862A4 (en) PHARMACEUTICAL METHODS AND COMPOSITIONS FOR IMPROVING THE ESTABLISHMENT OF EMBRYOS